Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial
Thaninee Prasoppokakorn, Supachaya Sriphoosanaphan, Nutbordee Nalinthassanai, Thitaporn Roongrawee, Pongtorn Hanboonkunupakarn, Pisit Tangkijvanich, Rungsun Rerknimitr
OBM Integrative and Complementary Medicine, doi:10.21926/obm.icm.2401013
Reports indicate that Andrographolide inhibits viral replication and reduces COVID-19 symptoms. This study aimed to determine Andrographolide's additional effect and safety in mild COVID-19 patients treated with favipiravir. A multicenter, open-labeled, randomized controlled trial was conducted from October 2021 to February 2022. The patients were randomized to receive a combination of Andrographolide and favipiravir or favipiravir monotherapy. The primary outcome was the occurrence rate of severe pneumonia. The secondary outcomes were symptom improvement, inflammatory biomarkers, and adverse events on days 7 and 14. 82 mild COVID-19 patients were enrolled; 43 and 39 patients received either combination therapy or favipiravir alone. Baseline characteristics were comparable. None developed severe pneumonia, requiring a mechanical ventilator. The Andrographolide group had a significant reduction of cough compared to the controlled group; 13 (30.2%) vs. 22 (56.4%), p = 0.017 on day 7 and 4 (9.3%) vs. 7 (17.9%), p = 0.025 on day 14. Moreover, the Andrographolide group had significantly lower levels of inflammatory markers on day 7, CRP (5.8 vs. 18.4 mg/L; p = 0.019) and IL-6 (2.0 vs. 21.8 pg/mL; p = 0.001) but not on day 14. Regarding safety outcomes, the Andrographolide group had significantly higher AST levels on day 7 (40.3 vs. 32.2 U/L; p = 0.030) and both AST and ALT levels on day 14 (55.3 vs. 32.0; p = 0.014 and 63.8 vs. 40.0; p = 0.022, respectively). In mild COVID-19 patients, the combination of Andrographolide and favipiravir did not demonstrate additional benefits over favipiravir alone in preventing severe pneumonia. However, Andrographolide significantly reduced cough symptoms, especially during the first week. Furthermore, despite mild transaminitis, patients treated with Andrographolide showed improvements in inflammatory markers.
Author Contributions Thaninee Prasoppokakorn, Supachaya Sriphoosanaphan, Rungsun Rerknimitr -Conceptual design of the work; Nutbordee Nalinthassanai, Thitaporn Roongrawee, Pongtorn Hanboonkunupakarn, Pisit Tangkijvanich -Data collection and data acquisition; Thaninee Prasoppokakorn, Supachaya Sriphoosanaphan, Rungsun Rerknimitr -Data analysis and interpretation; Thaninee Prasoppokakorn -Drafting the manuscript; Supachaya Sriphoosanaphan, Rungsun Rerknimitr -Critical revision of the manuscript; All authors -Final approval of the version to be published.
Competing Interests The authors declare no conflicts of interests.
References
Akbar, Andrographis paniculata: A review of pharmacological activities and clinical effects, Altern Med Rev
Damiati, Bahlas, Aljohaney, Bawazir, Mustafa et al., Implications of SARS-CoV-2 infection on the clinical, hematological, and inflammatory parameters in COVID-19 patients: A retrospective cross-sectional study, J Infect Public Health
Das, Das, Swain, Mukherjee, Bhattacharya, Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: An in silico study, Future Virol
Ergür, Yıldız, Şener, Kavurgacı, Ozturk, Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: A retrospective study, Sao Paulo Med J
Ferreira, Polonini, Dijkers, Postulated adjuvant therapeutic strategies for COVID-19, J Pers Med
Guérin, Mclean, Rashan, Lawal, Watson et al., Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis, PLoS Glob Public Health
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of favipiravir in treatment of COVID-19: A systematic review and metaanalysis of clinical trials, Sci Rep
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Li, Yuan, Wu, Zhen, Sun et al., Andrographolide, a natural anti-inflammatory agent: An update, Front Pharmacol
Nguyen, Do, Phan, Huynh, The potential of ameliorating COVID-19 and sequelae from andrographis paniculata via bioinformatics, Bioinform Biol Insights,
doi:10.1177/11779322221149622Puhach, Meyer, Eckerle, SARS-CoV-2 viral load and shedding kinetics, Nat Rev Microbiol
Qin, Kong, Shi, Wang, Ge, Andrographolide inhibits the production of TNF-α and interleukin-12 in lipopolysaccharide-stimulated macrophages: Role of mitogen-activated protein kinases, Biol Pharm Bull
Sa-Ngiamsuntorn, Suksatu, Pewkliang, Thongsri, Kanjanasirirat et al., Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component Andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives, J Nat Prod
Santos, Natural history of COVID-19 and current knowledge on treatment therapeutic options, Biomed Pharmacother
Shi, Huang, Chen, Pi, Hsu et al., Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage, Biochem Biophys Res Commun
Sirijatuphat, Manosuthi, Niyomnaitham, Owen, Copeland et al., Early treatment of favipiravir in COVID-19 patients without pneumonia: A multicentre, openlabelled, randomized control study, Emerg Microbes Infect
Siripongboonsitti, Ungtrakul, Tawinprai, Auewarakul, Chartisathian et al., Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial), Phytomedicine
Srikanth, Sarma, Andrographolide binds to spike glycoprotein and RNA-dependent RNA polymerase (NSP12) of SARS-CoV-2 by in silico approach: A probable molecule in the development of anti-coronaviral drug, J Genet Eng Biotechnol
Statsenko, Zahmi, Habuza, Almansoori, Smetanina et al., Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings, Front Cell Infect Microbiol
Vieillard-Baron, Flicoteaux, Salmona, Annane, Ayed et al., Epidemiological characteristics and severity of omicron variant cases in the APHP critical care units, MedRxiv,
doi:10.1101/2022.01.25.22269839Zhang, Lv, Zhou, Xie, Xu et al., Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial, Phytother Res
Zhu, Hou, Yang, Network pharmacology integrated with experimental validation revealed the anti-inflammatory effects of Andrographis paniculata, Sci Rep
{ 'indexed': {'date-parts': [[2024, 2, 3]], 'date-time': '2024-02-03T00:29:37Z', 'timestamp': 1706920177082},
'reference-count': 24,
'publisher': 'LIDSEN Publishing Inc',
'issue': '01',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2024, 2, 2]]},
'abstract': '<jats:p>Reports indicate that Andrographolide inhibits viral replication and reduces COVID-19 '
"symptoms. This study aimed to determine Andrographolide's additional effect and safety in "
'mild COVID-19 patients treated with favipiravir. A multicenter, open-labeled, randomized '
'controlled trial was conducted from October 2021 to February 2022. The patients were '
'randomized to receive a combination of Andrographolide and favipiravir or favipiravir '
'monotherapy. The primary outcome was the occurrence rate of severe pneumonia. The secondary '
'outcomes were symptom improvement, inflammatory biomarkers, and adverse events on days 7 and '
'14. 82 mild COVID-19 patients were enrolled; 43 and 39 patients received either combination '
'therapy or favipiravir alone. Baseline characteristics were comparable. None developed severe '
'pneumonia, requiring a mechanical ventilator. The Andrographolide group had a significant '
'reduction of cough compared to the controlled group; 13 (30.2%) vs. 22 (56.4%), p = 0.017 on '
'day 7 and 4 (9.3%) vs. 7 (17.9%), p = 0.025 on day 14. Moreover, the Andrographolide group '
'had significantly lower levels of inflammatory markers on day 7, CRP (5.8 vs. 18.4 mg/L; p = '
'0.019) and IL-6 (2.0 vs. 21.8 pg/mL; p = 0.001) but not on day 14. Regarding safety outcomes, '
'the Andrographolide group had significantly higher AST levels on day 7 (40.3 vs. 32.2 U/L; p '
'= 0.030) and both AST and ALT levels on day 14 (55.3 vs. 32.0; p = 0.014 and 63.8 vs. 40.0; p '
'= 0.022, respectively). In mild COVID-19 patients, the combination of Andrographolide and '
'favipiravir did not demonstrate additional benefits over favipiravir alone in preventing '
'severe pneumonia. However, Andrographolide significantly reduced cough symptoms, especially '
'during the first week. Furthermore, despite mild transaminitis, patients treated with '
'Andrographolide showed improvements in inflammatory markers.</jats:p>',
'DOI': '10.21926/obm.icm.2401013',
'type': 'journal-article',
'created': {'date-parts': [[2024, 2, 2]], 'date-time': '2024-02-02T08:29:15Z', 'timestamp': 1706862555000},
'page': '1-17',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Efficacy and Safety of Andrographolide and Favipiravir Versus Favipiravir Monotherapy in '
'Patients with Mild COVID-19 Infection: A Multicenter Randomized Controlled Trial',
'prefix': '10.21926',
'volume': '09',
'author': [ {'given': 'Thaninee', 'family': 'Prasoppokakorn', 'sequence': 'first', 'affiliation': []},
{ 'given': 'Supachaya',
'family': 'Sriphoosanaphan',
'sequence': 'additional',
'affiliation': []},
{'given': 'Nutbordee', 'family': 'Nalinthassanai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Thitaporn', 'family': 'Roongrawee', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Pongtorn',
'family': 'Hanboonkunupakarn',
'sequence': 'additional',
'affiliation': []},
{'given': 'Pisit', 'family': 'Tangkijvanich', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rungsun', 'family': 'Rerknimitr', 'sequence': 'additional', 'affiliation': []}],
'member': '9387',
'published-online': {'date-parts': [[2024, 2, 2]]},
'reference': [ { 'key': 'ref=1',
'doi-asserted-by': 'crossref',
'unstructured': 'Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, '
'Martinez-de-Hoyo R. The efficacy and safety of favipiravir in treatment '
'of COVID-19: A systematic review and meta-analysis of clinical trials. '
'Sci Rep. 2021; 11: 11022.',
'DOI': '10.1038/s41598-021-90551-6'},
{ 'key': 'ref=2',
'doi-asserted-by': 'crossref',
'unstructured': 'Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, '
'Charoenpong L, et al. Early treatment of favipiravir in COVID-19 '
'patients without pneumonia: A multicentre, open-labelled, randomized '
'control study. Emerg Microbes Infect. 2022; 11: 2197-2206.',
'DOI': '10.1080/22221751.2022.2117092'},
{ 'key': 'ref=3',
'doi-asserted-by': 'crossref',
'unstructured': 'Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role '
'of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021; '
'102: 501-508.',
'DOI': '10.1016/j.ijid.2020.10.069'},
{ 'key': 'ref=4',
'doi-asserted-by': 'crossref',
'unstructured': 'Vieillard-Baron A, Flicoteaux R, Salmona M, Annane D, Ayed S, Azoulay E, '
'et al. Epidemiological characteristics and severity of omicron variant '
'cases in the APHP critical care units. MedRxiv. 2022. doi: '
'10.1101/2022.01.25.22269839.',
'DOI': '10.1101/2022.01.25.22269839'},
{ 'key': 'ref=5',
'doi-asserted-by': 'crossref',
'unstructured': 'Qin LH, Kong L, Shi GJ, Wang ZT, Ge BX. Andrographolide inhibits the '
'production of TNF-α and interleukin-12 in lipopolysaccharide-stimulated '
'macrophages: Role of mitogen-activated protein kinases. Biol Pharm Bull. '
'2006; 29: 220-224.',
'DOI': '10.1248/bpb.29.220'},
{ 'key': 'ref=6',
'unstructured': 'Akbar S. Andrographis paniculata: A review of pharmacological activities '
'and clinical effects. Altern Med Rev. 2011; 16: 66-77.'},
{ 'key': 'ref=7',
'doi-asserted-by': 'crossref',
'unstructured': 'Nguyen HT, Do VM, Phan TT, Nguyen Huynh DT. The potential of '
'ameliorating COVID-19 and sequelae from andrographis paniculata via '
'bioinformatics. Bioinform Biol Insights. 2023; 17. doi: '
'10.1177/11779322221149622.',
'DOI': '10.1177/11779322221149622'},
{ 'key': 'ref=8',
'doi-asserted-by': 'crossref',
'unstructured': 'Li X, Yuan W, Wu J, Zhen J, Sun Q, Yu M. Andrographolide, a natural '
'anti-inflammatory agent: An update. Front Pharmacol. 2022; 13: 920435.',
'DOI': '10.3389/fphar.2022.920435'},
{ 'key': 'ref=9',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhu N, Hou J, Yang N. Network pharmacology integrated with experimental '
'validation revealed the anti-inflammatory effects of Andrographis '
'paniculata. Sci Rep. 2021; 11: 9752.',
'DOI': '10.1038/s41598-021-89257-6'},
{ 'key': 'ref=10',
'doi-asserted-by': 'crossref',
'unstructured': 'Das BS, Das NC, Swain SS, Mukherjee S, Bhattacharya D. Andrographolide '
'induces anti-SARS-CoV-2 response through host-directed mechanism: An in '
'silico study. Future Virol. 2022; 17: 651-673.',
'DOI': '10.2217/fvl-2021-0171'},
{ 'key': 'ref=11',
'doi-asserted-by': 'crossref',
'unstructured': 'Sa-Ngiamsuntorn K, Suksatu A, Pewkliang Y, Thongsri P, Kanjanasirirat P, '
'Manopwisedjaroen S, et al. Anti-SARS-CoV-2 activity of Andrographis '
'paniculata extract and its major component Andrographolide in human lung '
'epithelial cells and cytotoxicity evaluation in major organ cell '
'representatives. J Nat Prod. 2021; 84: 1261-1270.',
'DOI': '10.1021/acs.jnatprod.0c01324'},
{ 'key': 'ref=12',
'doi-asserted-by': 'crossref',
'unstructured': 'Srikanth L, Sarma PV. Andrographolide binds to spike glycoprotein and '
'RNA-dependent RNA polymerase (NSP12) of SARS-CoV-2 by in silico '
'approach: A probable molecule in the development of anti-coronaviral '
'drug. J Genet Eng Biotechnol. 2021; 19: 101.',
'DOI': '10.1186/s43141-021-00201-7'},
{ 'key': 'ref=13',
'doi-asserted-by': 'crossref',
'unstructured': 'Shi TH, Huang YL, Chen CC, Pi WC, Hsu YL, Lo LC, et al. Andrographolide '
'and its fluorescent derivative inhibit the main proteases of 2019-nCoV '
'and SARS-CoV through covalent linkage. Biochem Biophys Res Commun. 2020; '
'533: 467-473.',
'DOI': '10.1016/j.bbrc.2020.08.086'},
{ 'key': 'ref=14',
'doi-asserted-by': 'crossref',
'unstructured': 'Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, et al. Efficacy and '
'safety of Xiyanping injection in the treatment of COVID-19: A '
'multicenter, prospective, open-label and randomized controlled trial. '
'Phytother Res. 2021; 35: 4401-4410.',
'DOI': '10.1002/ptr.7141'},
{ 'key': 'ref=15',
'doi-asserted-by': 'crossref',
'unstructured': 'Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, '
'Chartisathian W, Jansala T, et al. Efficacy of Andrographis paniculata '
'extract treatment in mild to moderate COVID-19 patients being treated '
'with favipiravir: A double-blind, randomized, placebo-controlled study '
'(APFaVi trial). Phytomedicine. 2023; 119: 155018.',
'DOI': '10.1016/j.phymed.2023.155018'},
{ 'key': 'ref=16',
'unstructured': 'National Institutes of Health (NIH). Coronavirus disease 2019 (COVID-19) '
'treatment guidelines [Internet]. Bethesda, MD: National Institutes of '
'Health (NIH); 2023. Available from: '
'https://www.covid19treatmentguidelines.nih.gov/.'},
{ 'key': 'ref=17',
'doi-asserted-by': 'crossref',
'unstructured': 'Guérin PJ, McLean AR, Rashan S, Lawal A, Watson JA, Strub-Wourgaft N, et '
'al. Definitions matter: Heterogeneity of COVID-19 disease severity '
'criteria and incomplete reporting compromise meta-analysis. PLoS Glob '
'Public Health. 2022; 2: e0000561.',
'DOI': '10.1371/journal.pgph.0000561'},
{ 'key': 'ref=18',
'unstructured': 'Centers for Disease Control and Prevention. Underlying medical '
'conditions [Internet]. Atlanta, GA: Centers for Disease Control and '
'Prevention; 2023. Available from: '
'https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.'},
{ 'key': 'ref=19',
'doi-asserted-by': 'crossref',
'unstructured': 'Dos Santos WG. Natural history of COVID-19 and current knowledge on '
'treatment therapeutic options. Biomed Pharmacother. 2020; 129: 110493.',
'DOI': '10.1016/j.biopha.2020.110493'},
{ 'key': 'ref=20',
'doi-asserted-by': 'crossref',
'unstructured': 'Ferreira AO, Polonini HC, Dijkers EC. Postulated adjuvant therapeutic '
'strategies for COVID-19. J Pers Med. 2020; 10: 80.',
'DOI': '10.3390/jpm10030080'},
{ 'key': 'ref=21',
'doi-asserted-by': 'crossref',
'unstructured': 'Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding '
'kinetics. Nat Rev Microbiol. 2023; 21: 147-161.',
'DOI': '10.1038/s41579-022-00822-w'},
{ 'key': 'ref=22',
'doi-asserted-by': 'crossref',
'unstructured': 'Statsenko Y, Al Zahmi F, Habuza T, Almansoori TM, Smetanina D, Simiyu '
'GL, et al. Impact of age and sex on COVID-19 severity assessed from '
'radiologic and clinical findings. Front Cell Infect Microbiol. 2021; 11: '
'777070.',
'DOI': '10.3389/fcimb.2021.777070'},
{ 'key': 'ref=23',
'doi-asserted-by': 'crossref',
'unstructured': 'Damiati LA, Bahlas S, Aljohaney A, Bawazir Y, Mustafa M, Denetiu I, et '
'al. Implications of SARS-CoV-2 infection on the clinical, hematological, '
'and inflammatory parameters in COVID-19 patients: A retrospective '
'cross-sectional study. J Infect Public Health. 2022; 15: 214-221.',
'DOI': '10.1016/j.jiph.2021.12.013'},
{ 'key': 'ref=24',
'doi-asserted-by': 'crossref',
'unstructured': 'Ergür FÖ, Yıldız M, Şener MU, Kavurgacı S, Ozturk A. Adverse effects '
'associated with favipiravir in patients with COVID-19 pneumonia: A '
'retrospective study. Sao Paulo Med J. 2022; 140: 372-377.',
'DOI': '10.1590/1516-3180.2021.0489.r1.13082021'}],
'container-title': 'OBM Integrative and Complementary Medicine',
'original-title': [],
'deposited': { 'date-parts': [[2024, 2, 2]],
'date-time': '2024-02-02T08:29:41Z',
'timestamp': 1706862581000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.lidsen.com/journals/icm/icm-09-01-013'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 2, 2]]},
'references-count': 24,
'journal-issue': { 'issue': '01',
'published-online': {'date-parts': [[2024]]},
'published-print': {'date-parts': [[2024]]}},
'URL': 'http://dx.doi.org/10.21926/obm.icm.2401013',
'relation': {},
'ISSN': ['2573-4393'],
'subject': ['General Medicine'],
'container-title-short': 'OBM Integr Complement Med',
'published': {'date-parts': [[2024, 2, 2]]}}
